VX-659 + Tezacaftor + Ivacaftor - A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
The Portland Hospital 205-209 Great Portland St,, UK
chris.nolan@gmail.com.test +44 20 3627 1534
